From the Guidelines
The recommended dosing regimen for SKIRIZY (risankizumab) in treating moderate to severe plaque psoriasis is 150 mg given by self-administered subcutaneous injection at weeks 0,4, and then every 12 weeks. This dosing regimen is based on the joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics, which provides a strength of recommendation of A for this dosing schedule 1. The guidelines suggest that risankizumab can be used as monotherapy in adult patients with moderate-to-severe plaque psoriasis, with a strength of recommendation of B 1.
Key points to consider when administering SKIRIZY include:
- The medication should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) and protected from light.
- Patients or caregivers may self-administer the injection after proper training in subcutaneous injection technique.
- The injection sites should be rotated and should not be given in areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis.
- Before initiating treatment, patients should be evaluated for tuberculosis infection and complete any necessary immunizations, as SKIRIZY may increase the risk of infections.
It is essential to follow the recommended dosing regimen and administration guidelines to ensure the safe and effective use of SKIRIZY in treating moderate to severe plaque psoriasis, as supported by the highest quality evidence available 1.
From the FDA Drug Label
2.3 Recommended Dosage for Plaque Psoriasis The recommended dosage is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
The recommended dosing regimen for SKIRIZY (risankizumab) in treating moderate to severe plaque psoriasis is 150 mg administered by subcutaneous injection at:
- Week 0
- Week 4
- Every 12 weeks thereafter 2
From the Research
Recommended Dosing Regimen for SKIRIZY (Risankizumab)
The recommended dosing regimen for SKIRIZY (risankizumab) in treating moderate to severe plaque psoriasis is as follows:
- 150 mg administered subcutaneously at weeks 0 and 4, and every 12 weeks thereafter 3
- This dosing regimen has been shown to be effective in achieving maximum efficacy with no apparent correlation between risankizumab exposure and safety 3
Administration Options
Risankizumab can be administered via:
- Prefilled syringe (PFS) 4
- Autoinjector (AI) 4
- Both administration options have been shown to be effective and well-tolerated 4
Efficacy and Safety
The efficacy and safety of risankizumab have been demonstrated in several studies, including:
- Pivotal phase III trials (UltIMMa-1, UltIMMa-2, IMMvent, and IMMhance) 5
- Head-to-head trials comparing risankizumab to other treatments such as secukinumab and fumaric acid esters 5
- Long-term extension studies, including the LIMMitless trial 6
- Studies evaluating the efficacy and safety of risankizumab in patients with suboptimal response to other treatments, such as secukinumab or ixekizumab 7